This Experimental Drug Repaired the Gut and Reversed Severe Fatty Liver Disease

An experimental compound called DT-109 reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models by restoring intestinal barrier integrity and reducing harmful bacterial ammonia production, with especially promising results in nonhuman primates whose gut microbiota resembles humans more closely.